mRNA expression in palmitate treated myotubes from premenopausal and postmenopausal women.

<p>Satellite cells were isolated from vastus lateralis biopsies from premenopausal and postmenopausal women. Cells were grown in culture until mature myotubes were formed. Myotubes were treated with palmitate (300 µM) in the last one, two or three days of differentiation. The mRNA levels of analyzed genes and the endogenous control 18S were determined by quantitative real time PCR. mRNA expression in pre-myotubes (n = 6, black bars) and post-myotubes (n = 5, white bars) following zero-, one-, two- or three days of palmitate treatment (300 µM), (A) There was a menopause*palmitate interaction on SPT1, as one day of palmitate treatment led to a significant increase in SPT1 mRNA in post-myotubes. Furthermore, one day of palmitate treatment led to a significantly higher expression of SPT1 mRNA in post-myotubes compared to pre-myotubes. Three days of palmitate treatment increased SPT1 expression significantly in pre-myotubes, compared to the control, (B) CPTI mRNA expression increased significantly in response to palmitate treatment in myotubes from both groups, (C) β-HAD mRNA expression increased significantly in response to palmitate treatment in myotubes from both groups, (D) PPARα mRNA expression was unaffected by both palmitate treatment and menopausal status, (E) PGC-1α mRNA expression was unaffected by both palmitate treatment and menopausal status, (F) CS mRNA expression was unaffected by both palmitate treatment and menopausal status, 18S was used as the house keeping gene and did not differ between groups. 0: Zero days of palmitate treatment (control), 1: One day of palmitate treatment, 2: Two days of palmitate treatment, 3: Three days of palmitate treatment. Significantly different from control; * p<0.05. Significantly different from premenopausal, at same palmitate exposure time; # p<0.05. All data were normalized to the premenopausal control group. Data are presented as means ± SEM.